Current Affairs - International - Discussion

Australia’s Therapeutic Goods Administration (TGA) approved Lecanemab (marketed as Leqembi) for treating early-stage Alzheimer’s disease, making it the second disease-modifying therapy cleared in the country. Lecanemab is a monoclonal antibody that targets amyloid-beta plaques, slowing cognitive decline and disease progression in patients with mild Alzheimer’s or mild cognitive impairment. Approval comes with safety measures, including MRI monitoring, due to risks like brain swelling and microhemorrhages. While the drug offers hope to early-stage patients, its high cost and limited accessibility remain challenges. This approval reflects Australia’s commitment to advancing dementia care and addressing rising Alzheimer’s prevalence.